Plasma Fractionation Market by Product, Application, End-User

Description

List of Tables

[197 Pages Report] The Plasma Fractionation Market size was estimated at USD 35.52 billion in 2023 and expected to reach USD 38.95 billion in 2024, at a CAGR 10.45% to reach USD 71.27 billion by 2030.

Plasma fractionation refers to collecting, separating, and purifying various essential components present in human plasma, primarily including albumin, immunoglobulins, coagulation factors, and other proteins. These components have many applications in medical treatments, such as hemophilia therapy, immunity disorders treatment, wound healing support, neurology therapy, and other rare diseases. The demand for source plasma has been steadily increasing due to its role as a vital ingredient in several life-saving therapies. This surge can be attributed to an aging population prone to chronic illnesses requiring blood-based therapies and the rising prevalence of immune disorders. In addition, rising awareness about blood-related diseases among patients contributes significantly to this market's expansion. However, stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies may hamper the market demand. New advancements in production technology further boost opportunities for the players involved in this field. Moreover, strategic collaborations among various stakeholders drive innovative research work within the industry that provides novel solutions and is expected to create a lucrative market opportunity in the forecasted period.

KEY MARKET STATISTICS
Base Year [2023]	USD 35.52 billion
Estimated Year [2024]	USD 38.95 billion
Forecast Year [2030]	USD 71.27 billion
CAGR (%)	10.45%

Product: Rising use of plasma fractionation for immunoglobulins purification

Albumin is a major plasma protein critical in regulating blood volume and transporting various substances, including hormones, drugs, and nutrients. It primarily treats hypovolemia (low blood volume), hypoalbuminemia (low albumin levels), and severe burns. Coagulation factor concentrates are essential for treating bleeding disorders such as hemophilia A & B and von Willebrand disease and replace missing or deficient clotting factors, preventing excessive bleeding and promoting proper wound healing. Immunoglobulins are antibodies that play a crucial role in the body's immune response by neutralizing pathogens such as bacteria and viruses and are used to treat primary immunodeficiency diseases, inflammatory and autoimmune disorders, and certain types of cancer. Protease inhibitors are essential for managing hereditary angioedema (HAE), a periodic genetic condition characterized by recurrent episodes of severe swelling in various body parts. These inhibitors block the action of proteases responsible for inflammation and vascular permeability during hereditary angioedema (HAE) attacks.

Application: Proliferating use to treat hematological disorders

In the critical care setting, plasma fractionation products are vital for treating life-threatening conditions such as sepsis, burns, and trauma. Plasma fractionation has significant applications in hemato-oncology for managing blood-related cancers and supporting chemotherapy treatments. Hematology involves the prevention, diagnosis, and treatment of blood diseases such as hemophilia or von Willebrand disease (VWD). Plasma fractionation products including IVIG are increasingly used in treating neurological conditions, including Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and multiple sclerosis. In pulmonology, plasma fractionation helps in managing respiratory diseases such as alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS). Plasma fractionation is utilized in rheumatology primarily through the use of IVIG to manage autoimmune and inflammatory disorders.

End-User: Extensive use of plasma fractionation in clinical research laboratories to ensure the safety and efficacy of plasma-derived products

Academic & research institutes are engaged in basic research to advance the understanding of plasma proteins and their therapeutic potential. The key needs for this segment include high-purity plasma fractions for protein characterization studies, advanced fractionation techniques that can lead to discoveries, and access to reliable sources of raw material. Clinical research laboratories are essential for testing and validating plasma fractionation processes and products. They conduct trials to ensure the safety and efficacy of plasma-derived products, assess their impact on patients, and gather data to support regulatory approval. These laboratories are involved in both pre-clinical and clinical stages of product development.

Regional Insights

The Americas has a significant market presence in the plasma fractionation market due to a well-established healthcare infrastructure, high prevalence of immunodeficiency diseases, and an increasing geriatric population. In Europe, EU countries have a strong regulatory framework governing the plasma fractionation industry. The European Medicines Agency (EMA) regulates manufacturing practices and oversees quality standards for blood-derived products, significantly driving the region's market demand. The MEA region presents lucrative opportunities due to rising incomes and expanding access to healthcare services. The Asia-Pacific observed a developing landscape in the plasma fractionation market owing to rapid urbanization and economic development that is driving investments in healthcare infrastructure. Additionally, there is an increasing focus on blood safety regulations by governments in the APAC region, presenting opportunities for market players.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Plasma Fractionation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Plasma Fractionation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Plasma Fractionation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, ADMA Biologics, Inc., Bharat Serums and Vaccines Limited, Bio Products Laboratory Ltd., Biotest AG by Grifols, S.A., China Biologic Products, Inc., CSL Limited, Emergent BioSolutions Inc., Fusion Health Care Pvt. Ltd., GC Biopharma corp., Grifols, S.A., HEINKEL Process Technology GmbH, Hemarus Therapeutics Ltd, Intas Pharmaceuticals Ltd., Kamada Ltd., Kedrion S.p.A., LFB SA, Merck KGaA, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions B.V., Sanquin, Shanghai Raas Blood Products Co. Ltd, SK Plasma Co.,Ltd., STERIS plc, and Takeda Pharmaceutical Company Ltd.

Market Segmentation & Coverage

This research report categorizes the Plasma Fractionation Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Albumin
- Coagulation Factor Concentrates
  - Factor IX
  - Factor VIII
  - Factor XIII
  - Fibrinogen Concentrates
  - Prothrombin Complex Concentrate
  - Von Willebrand Factor

Immunoglobulin
- Intravenous Immunoglobulin
- Subcutaneous Immunoglobulin

Protease Inhibitors

Application
- Critical Care
- Hemato-Oncology
- Hematology
- Neurology
- Pulmonology
- Rheumatology

End-User
- Academic & Research Institutes
- Clinical Research Laboratories

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Plasma Fractionation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Plasma Fractionation Market?

3. What are the technology trends and regulatory frameworks in the Plasma Fractionation Market?

4. What is the market share of the leading vendors in the Plasma Fractionation Market?

5. Which modes and strategic moves are suitable for entering the Plasma Fractionation Market?

Product Code: MRR-4312A385A58A

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Improving access to plasma-based therapies and high use of immunoglobulins in various therapeutic areas
  - 5.1.1.2. Government initiatives to increase plasma collection
  - 5.1.1.3. Growing prevalence of elderly people around the globe and the increasing number of blood collection facilities
- 5.1.2. Restraints
  - 5.1.2.1. Presence of new pathogenic agents that resist the present viral inactivation treatments
- 5.1.3. Opportunities
  - 5.1.3.1. Continuous advancements in process development technology for improved formulations
  - 5.1.3.2. Exponential utilization in new clinical trials and growing R&D activities in plasma treatment
- 5.1.4. Challenges
  - 5.1.4.1. Stringent government regulations on plasma fractionation and the presence of alternative recombinant therapies
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising use of plasma fractionation for immunoglobulins purification
- 5.2.2. Application: Proliferating use to treat hematological disorders
- 5.2.3. End-User: Extensive use of plasma fractionation in clinical research laboratories to ensure the safety and efficacy of plasma-derived products
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Plasma Fractionation Market, by Product

6.1. Introduction
6.2. Albumin
6.3. Coagulation Factor Concentrates
6.4. Immunoglobulin
6.5. Protease Inhibitors

7. Plasma Fractionation Market, by Application

7.1. Introduction
7.2. Critical Care
7.3. Hemato-Oncology
7.4. Hematology
7.5. Neurology
7.6. Pulmonology
7.7. Rheumatology

8. Plasma Fractionation Market, by End-User

8.1. Introduction
8.2. Academic & Research Institutes
8.3. Clinical Research Laboratories

9. Americas Plasma Fractionation Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Plasma Fractionation Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Plasma Fractionation Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations
- 12.3.2. CSL's USD470 Million Plasma Fractionation Facility Opens in Marburg, Germany
- 12.3.3. Takeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in Japan
- 12.3.4. Kedrion presented at plasma fractionation workshop in Saudi Arabia
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio